The move helps in expediting the enrolment process for central nervous system, vaccine, as well as specialty trials.

Tempus AI TEM is entering a phase of strong operating momentum, backed by significant acceleration in both revenues and gross profit. This trend became particularly clear in the company’s last two ...

A panelist discusses how the POD1UM-303 randomized phase 3 trial demonstrated that adding retifanlimab (a PD-1 inhibitor) to ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...